Novo Nordisk can add data showing Tresiba can reduce the risk of hypoglycaemia to its label, a development which should help its fight competition from cheaper alternatives. The FDA has ruled that ...

Novo Nordisk’s strong intangible assets in diabetes ... and Novo could achieve a strong share in these nascent markets. Tresiba’s strong profile in the long-acting insulin market hasn ...

Novo Nordisk has beaten Wall Street's revenue estimates ... [$7.09] due to my more optimistic sales expectations for Tresiba, Sogroya, Wegovy, NovoSeven, and Ozempic, as well as the launches ...

Novo Nordisk, a Danish pharmaceutical company, has signed a major deal worth up to $2 billion for the rights to a new obesity and diabetes drug, the company announced March 24. The drug ...

https://www.tipranks.com/news/the-fly/novo-nordisk-warns-of-counterfeit-ozempic-injections Novo Nordisk (NVO) said it has become aware of several hundred units of ...